GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actavia Life Sciences Inc (OTCPK:RASP) » Definitions » PS Ratio

Actavia Life Sciences (Actavia Life Sciences) PS Ratio : (As of Jun. 09, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Actavia Life Sciences PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Actavia Life Sciences's share price is $0.009. Actavia Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00. Hence, Actavia Life Sciences's PS Ratio for today is .

The historical rank and industry rank for Actavia Life Sciences's PS Ratio or its related term are showing as below:

RASP's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.53
* Ranked among companies with meaningful PS Ratio only.

Actavia Life Sciences's Revenue per Sharefor the three months ended in Mar. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00.

Back to Basics: PS Ratio


Actavia Life Sciences PS Ratio Historical Data

The historical data trend for Actavia Life Sciences's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actavia Life Sciences PS Ratio Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Actavia Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Actavia Life Sciences's PS Ratio

For the Biotechnology subindustry, Actavia Life Sciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actavia Life Sciences's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actavia Life Sciences's PS Ratio distribution charts can be found below:

* The bar in red indicates where Actavia Life Sciences's PS Ratio falls into.



Actavia Life Sciences PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Actavia Life Sciences's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.009/0
=

Actavia Life Sciences's Share Price of today is $0.009.
Actavia Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Actavia Life Sciences  (OTCPK:RASP) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Actavia Life Sciences PS Ratio Related Terms

Thank you for viewing the detailed overview of Actavia Life Sciences's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Actavia Life Sciences (Actavia Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 2525, New York, NY, USA, 10170
Rasna Therapeutics Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.

Actavia Life Sciences (Actavia Life Sciences) Headlines

No Headlines